On March 13, 2024, Truist Securities analyst Srikripa Devarakonda reaffirmed a positive outlook on Keros Therapeutics (NASDAQ: KROS), maintaining a Buy rating and setting a $100 price target. This reaffirmation aligns with the current consensus rating for KROS, which stands at “Buy” based on feedback from 16 analysts, including 8 buy and 7 strong buy recommendations. According to Tipranks, the average price target for Keros Therapeutics is $82.22, with a high estimate of $105.00 and a low estimate of $60.00, indicating a potential upside of 23.01%.
The surge in Keros Therapeutics’ shares was initially observed on April 21, 2023.
KROS Stock Shows Strong Performance Near 52-Week High and Above 200-Day Moving Average on March 13, 2024
On March 13, 2024, KROS stock showed strong performance as it traded near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been on an upward trend over the long term.
The price of KROS shares increased by $0.31 since the market last closed, representing a 0.46% rise. The stock opened at $67.68, $0.13 higher than its previous close.
Investors may be optimistic about KROS’s prospects, leading to the increase in share price. The stock’s performance on March 13, 2024, indicates that there is strong demand for KROS shares, potentially driven by positive news or developments related to the company.
It is important for investors to continue monitoring KROS stock performance to see if the upward trend continues. Keeping an eye on key technical indicators, such as the moving averages and trading range, can help investors make informed decisions about buying or selling KROS shares.
Overall, the performance of KROS stock on March 13, 2024, reflects positive momentum and investor confidence in the company’s future prospects.
KROS Stock Performance Analysis: Negative Net Income and Declining EPS Trends – March 13, 2024
On March 13, 2024, KROS stock experienced mixed performances based on the available data from CNN Money. The company’s total revenue information was currently unavailable, making it difficult to provide a comprehensive analysis of its financial health. However, we can glean some insights from the net income and earnings per share figures provided.
According to the data, KROS reported a net income of -$152.99 million over the past year, which represents a significant decrease of 46.15% compared to the previous year. In the fourth quarter alone, the company’s net income stood at -$40.24 million, showing a slight improvement of 0.0% from the previous quarter. These figures indicate that KROS has been facing challenges in generating profits, as evidenced by the negative net income numbers.
Similarly, the earnings per share (EPS) figures for KROS also reflect a downward trend. The company reported an EPS of -$5.20 over the past year, marking a decrease of 25.28% compared to the previous year. In the fourth quarter, the EPS was -$1.34, showing no change from the previous quarter. This decline in EPS suggests that KROS’s profitability per share has been diminishing over time.
Overall, the data on KROS stock performances on March 13, 2024, suggests that the company is facing financial difficulties, as evidenced by the negative net income and declining EPS figures. Investors and analysts may need to closely monitor KROS’s financial health and performance indicators to assess its future prospects and potential for growth. It is essential for stakeholders to conduct further research and analysis to gain a better understanding of KROS’s current position in the market and its outlook for the future.
